Nimbus Therapeutics pulls in $43 mln

Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company’s previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.

VC-backed Cidara Therapeutics files for IPO

San Diego-based biotech company Cidara Therapeutics has filed for a $69 million IPO, according to an SEC filing. The company plans on trading on the NASDAQ under the ticker symbol “CDTX.” Jefferies and Leerink Partners are listed as lead underwriters. Cidara’s backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.

Prevtec Microbia scores $4.7 mln

Canadian biotech company Prevtec Microbia has raised $4.7 million in funding. The investors included VVC, Telesystem Ltd, Groupe Jafaco Gestion Inc and Desjardins-Innovatech, S.E.C.

Cidara Therapeutics snags $42 mln Series B

San Diego-based biotech firm Cidara Therapeutics Inc has closed $42 million in Series B funding. The investors in this round were not named; however, the firm’s previous backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.

Biotech company ORIG3N scores $3.1 mln

Boston-based biotech company ORIG3N has closed $3.1 million in funding. The investors included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.

105 Views

VC-backed Ascendis Pharma goes public

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.

135 Views

Biotech firm RetroSense Therapeutics picks up $6 mln

Ann Arbor, Michigan-based biotech firm RetroSense Therapeutics has received $6 million in a Series A financing. The investors included Nerveda, Blue Water Angels, SDL Ventures, Tech Coast Angels and Michigan Economic Development Corp.

175 Views

Deerfield and Roche lead $10 mln round for AveXis

Dallas-based gene therapy-focused biotech firm AveXis has raised $10 million in funding. Deerfield Management and Roche Venture Fund led the round. In addition to the funding, AveXis has added Jonathan Leff of Deerfield and Carole Nuechterlein of Roche Venture Fund to its board of directors.

101 Views

Moderna Therapeutics scores $450 mln

Cambridge Mass.-based biotech firm Moderna Therapeutics has closed $450 million in funding. The backers in this round include Viking Global Investors, Invus, RA Capital Management, Wellington Management Company, AstraZeneca and Alexion Pharmaceuticals.

CytomX grabs $20 mln Series C

Biotech firm CytomX has received $20 million in Series C financing. Pfizer Venture Investments led the round with participation from previous backers Third Rock Ventures, Canaan Partners and the Roche Venture Fund. In addition to the funding, Dr. Elaine Jones, executive director of venture capital at Pfizer Venture Investments, has been added to CytomX’s board of directors. Her appointment becomes effective January 15, 2015.

Symic Biomedical snags $15 mln Series A

San Francisco-based Symic Biomedical, a healthcare-focused biotech firm, has raised $15 million in Series A funding. Lilly Ventures led the round with participation from other investors that included Den Danske Forskningsfond, Mitsui Global Investment, Ally Bridge Group, InCube Ventures, Purdue Foundry Investment Fund, Mission Bay Capital and QB3 Partners. In addition to the funding, Symic Biomedical has appointed Dr. Armen Shanafelt, a general partner at Lilly Ventures and Dr. Claus Christiansen, chairman of Nordic Biosciences, to its board of directors.

Ayoxxa nets additional Series B funds

Ayoxxa Biosystems, a biotech firm in Germany and Singapore, has received an additional 2.3 million euros in its Series B funding. The investors in this round were BioMedPartners AG and Grazia Equity GmbH. Also, the company has named Andreas Richter as chief financial officer. His appointment becomes effective January 1, 2015.

Biotech firm FibroGen goes public

San Francisco biotech firm FibroGen has raised $145.8 million for its IPO after pricing its 8.1 million shares at $18 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “FGEN.” Goldman Sachs, Citigroup and Leerink Partners are the lead underwriters.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget